logo dark logoo light logo
  • 主頁
  • AM1480
  • AM1380
  • 華語電視 Sino TV
  • 聯繫我們
  • 抗疫送暖
logo dark logoo light logo
  • 主頁
  • AM1480
  • AM1380
  • 華語電視 Sino TV
  • 聯繫我們
  • 抗疫送暖
mobile logo
  • 主頁
  • AM1480
  • AM1380
  • 華語電視 Sino TV
  • 聯繫我們
  • 抗疫送暖
November 5, 2021
美國要聞

輝瑞稱其新冠口服藥能降89%重症風險

輝瑞公司5日表示,其抗新冠口服藥可以使輕度和中度患者住院或死亡概率降低89%,並計劃本月將研究結果提交給食品藥物管理局 FDA尋求批准。

輝瑞週五表示,其新冠口服藥的臨床試驗顯示,這種藥在阻止住院或死亡方面非常成功,因此該公司提前終止了試驗,希望公眾可以更早從中受益。

輝瑞在一份新聞稿中表示,這種抗病毒藥物與低劑量的愛滋病藥物利托那韋結合使用,可以將新冠高風險患者住院或死亡減少高達89%。

實驗數據顯示,感染三天內服用藥物的感染者,僅有0.8%的人需要入院治療,無人死亡。服用安慰劑的對照組,有7%感染者住院或死亡,在第五天開始服用藥物,實驗結果相似。輝瑞表示,這一結果在統計學上具有高度顯著性。

輝瑞首席執行官博拉在一份聲明中稱,該藥可能會「改變遊戲規則」。

FDA顧問定於11月30日開會,討論緊急批准默克新冠口服藥的事宜。

分享:

SHARE THIS ARTICLE

by sukie
0
0
Related Posts
剛復工 雅培密州奶粉工廠受風暴影響再停產
June 16, 2022
美國要聞
美洲峰會揭幕 拜登:民主是美洲發展不可缺要素
June 10, 2022
美國要聞
控槍案兩黨協商關鍵階段 白宮傳願接受讓步版本
June 9, 2022
美國要聞
不滿白宮疫苗政策 18州提起訴訟
Previous post 不滿白宮疫苗政策 18州提起訴訟
Next post 紐約市公共倡導者威廉姆斯宣佈競選紐約州州長
紐約市公共倡導者威廉姆斯宣佈競選紐約州州長

即時新聞

5月新屋銷售意外上升 消費者信心指數創新低

June 24, 2022

歐盟商會:23%歐企考慮放棄投資中國

June 21, 2022

國際航空運輸協會:2023年有望重回盈利

June 21, 2022

雷克斯島再有囚犯死亡 今年第七人

June 21, 2022

曼哈頓東哈林區街頭槍擊案 致一死八傷

June 21, 2022
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

SAVE & ACCEPT

Terms and Conditions - Privacy Policy